Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-41 (Canceled)

42. (Currently Amended) An antibody that specifically binds to Factor D, or a Factor D binding fragment thereof, which completely inhibits alternative pathway complement activation at a molar ratio of about 1.5:1 (antibody to Factor D).

43. (Previously Presented) The antibody or binding fragment of claim 42, wherein the inhibition of complement activation is determined *in vitro*.

44. (Previously Presented) The antibody or binding fragment of claim 42, wherein the inhibition of complement activation is determined *ex vivo*.

45. (Currently Amended) An antibody or binding fragment thereof, that binds to a region of human factor D from amino acid residue Cys154 to Cys170 (inclusive) and completely inhibits alternative pathway complement activation at a molar ratio of about 1.5:1 (antibody to Factor D).

46. (Previously Presented) The antibody or binding fragment of claim 45, wherein the antibody or fragment does not bind to human factor D if amino acid residues Arg156, His159 and Leu168 are absent.

47. (Previously Presented) The antibody fragment of claim 42, wherein the fragment is Fab, $F(ab')_2$, Fv or single chain Fv.

48. (Previously Presented) The antibody or binding fragment of claim 42, wherein the antibody is a chimeric, humanized, deimmunised or human antibody.

49. (Currently Amended) The monoclonal antibody designated 166-32 produced by the hybridoma cell line deposited under ATCC Accession Number HB-12476.

50. (Previously Presented) The hybridoma producing the monoclonal antibody 166-32 of claim 49, deposited at the American Type Culture Collection under Accession number HB-12476.

51. (Currently Amended) An antibody or binding fragment thereof, that binds to the same epitope on factor D as the antibody designated 166-32 produced by the hybridoma cell line deposited under ATCC Accession Number HB-12476 and which completely inhibits alternative pathway complement activation at a molar ratio of about 1.5:1 (antibody to factor D).

52. (Previously Presented) The antibody fragment of claim 51, wherein the fragment is Fab, $F(ab')_2$, Fv or single chain Fv.

53. (Previously Presented) The antibody of claim 51, wherein the antibody is a chimeric, humanized, deimmunised or human.

54. (Previously Presented) A cell line producing the antibody or binding fragment of claim 51.

55. (Previously Presented) A cell line producing the chimeric Fab fragment of claim 52.

56. (Currently Amended) The chimeric form of the antibody of claim 51, having a mouse variable region of the monoclonal antibody designated 166-32 produced by the hybridoma cell line deposited under ATCC Accession Number HB-12476 and a human constant region.

57. (Previously Presented) The chimeric form of the antibody of claim 51, having a mouse variable region and a human constant region, of the Fab fragment of the monoclonal antibody 166-32.

58. (Previously Presented) A method of ameliorating a disease or condition mediated by excessive or uncontrolled activation of the complement system comprising administering an effective amount of the antibody according to claim 42 to inhibit the excessive or uncontrolled activation of the complement system.

59. (Previously Presented) The method according to claim 58, wherein the antibody is administered to a patient undergoing an operation involving cardiopulmonary bypass.

60. (Previously Presented) The method according to claim 59, wherein the antibody or binding fragment thereof is administered *in vivo*.

61. (Previously Presented) The method according to claim 59, wherein the antibody or binding fragment thereof is administered *ex vivo*.